01
Cash & equivalents increased 291.9%
Cash & equivalents changed +291.9% from the comparable as-filed period.
$42.3M→$165.9MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSagimet Biosciences Inc.'s latest supported as-filed period reports revenue of $2.0M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +291.9% from the comparable as-filed period.
Net income changed -34.3% from the comparable as-filed period.
Operating income changed -32.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SGMT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-354018SEC ↗8-KAug 13, 2026Period Aug 13, 20260001193125-26-347854SEC ↗4Aug 12, 2026Period Aug 11, 20260001193125-26-347407SEC ↗8-KAug 11, 2026Period Aug 11, 20260001193125-26-343446SEC ↗10-QAug 11, 2026Period Jun 30, 20260001193125-26-343441SEC ↗4Jul 22, 2026Period Jul 20, 20260001193125-26-312397SEC ↗4Jul 22, 2026Period Jul 20, 20260001193125-26-312394SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026Filed Aug 17, 2026 | Kemble GeorgeDirector | Option ExerciseDirect | 326,618 | $6 | $2.1M | Form 4 ↗ |
| Aug 14, 2026Filed Aug 17, 2026 | Kemble GeorgeDirector | Option ExerciseDirect | 24,369 | $6 | $154,987 | Form 4 ↗ |
| Aug 14, 2026Filed Aug 17, 2026 | Kemble GeorgeDirector | Open Market SaleDirect | 350,987 | $10 | $3.6M | Form 4 ↗ |
| Aug 14, 2026Filed Aug 17, 2026 | Kemble GeorgeDirector | Option ExerciseDirect | 326,618 | $0 | $0 | Form 4 ↗ |
| Aug 14, 2026Filed Aug 17, 2026 | Kemble George |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +59.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +131.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-312386| Option ExerciseDirect |
| 24,369 |
| $0 |
| $0 |
| Form 4 ↗ |